AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment


June 18 (Reuters) - British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April.

Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co , can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said.

BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.

AstraZeneca has been pushing to build its cancer drug portfolio and Lynparza is an important growth driver for the drugmaker, with analysts pegging the drug to hit $2.5 billion in sales in 2023, according to Refinitiv Eikon data.

Lynparza also helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening, late-stage clinical trial data from earlier this month showed.

This article appears in: World Markets , Stocks , Economy , Technology
Referenced Symbols: AZN ,

More from Reuters


See Reuters News

Research Brokers before you trade

Want to trade FX?